UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

October 18, 2022

Beth Y. Karlan, MD, discusses the current landscape of research investigating the efficacy of PARP inhibitor combination therapies for the treatment of patients with ovarian cancer.

June 01, 2022

New systemic regimens are being integrated into the treatment paradigm for resectable non–small cell lung cancer in the neoadjuvant and adjuvant settings, expanding options for patients with earlier-stage disease who face a challenging prognosis.

May 12, 2022

Lindsay L. Kroener, MD, discusses fertility preservation in patients with breast cancer.

April 12, 2022

The addition of the investigational anti-CD39 antibody TTX-030 to frontline treatment with the PD-L1 inhibitor budigalimab and mFOLFOX6 was determined to be safe and tolerable in patients with locally advanced or metastatic HER2-negative gastroesophageal junction adenocarcinoma.

April 08, 2022

Sara A. Hurvitz, MD, medical oncologist and medical director at the Jonsson Comprehensive Cancer Center Clinical Research Unit, discussed pivotal findings in the HER2-positive treatment landscape that possess the potential to change practice.

March 09, 2022

Sara A. Hurvitz, MD, discusses the benefit of trastuzumab deruxtecan in a subset of patients with HER2-positive breast cancer and active brain metastases in the phase 3 DESTINY-Breast03 trial.

March 08, 2022

Sara A. Hurvitz, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

March 05, 2022

The integration of HER2-targeted therapies into the treatment paradigm for patients with early-stage breast cancer, specifically the standard trastuzumab, has shifted focus away from whether patients should receive to how and when they should receive treatment with these agents.

March 04, 2022

Sara A. Hurvitz, MD, discusses utilizing CDK4/6 inhibitors in hormone receptor-positive breast cancer.

March 03, 2022

Dr Hurvitz sheds light on shifts in practice patterns in HER2-positive breast cancer in light of data that emerged in 2021, remaining questions regarding treatment sequencing, the importance of updates to the National Comprehensive Cancer Network guidelines in metastatic HER2-positive breast cancer, and future directions to keep an eye on in 2022.

January 31, 2022

Sara A. Hurvitz, MD, discusses progress made in 2021 with antibody-drug conjugates in HER2-positive breast cancer.

January 31, 2022

Cortney Eakin, MD, discusses racial disparities and histology trends in uterine cancer.

January 30, 2022

Cortney Eakin, MD, discusses alarming trends in uterine cancer histologies in Black women and some of the potential underlying risk factors at play.

January 27, 2022

UCLA Jonsson Comprehensive Cancer Center researchers have uncovered a potential new way to target pancreatic tumors that express high intratumoral interferon signaling

January 20, 2022

Although pembrolizumab monotherapy showed noninferiority to chemotherapy for overall survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma and a PD-L1 combined positive score of 1 or higher, and a clinically meaningful benefit over chemotherapy in those with a CPS of 10 or higher, pembrolizumab plus chemotherapy failed to show superiority over chemotherapy alone in either subset.

January 14, 2022

Sara A. Hurvitz, MD, discusses the clinical implications of the ongoing phase 2 SUMMIT trial in HER2-mutated breast cancer.

January 13, 2022

The addition of ADXS-503 to the treatment of patients with metastatic non–small cell lung cancer who were progressing on pembrolizumab (Keytruda) resulted in encouraging responses and durable disease control, according to findings from the phase 1/2 trial.

December 16, 2021

Preliminary research with datopotamab deruxtecan has shown a promising, unprecedented duration of response in heavily pretreated patients with non–small cell lung cancer.

December 14, 2021

Sara A. Hurvitz, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

December 01, 2021

Edward B. Garon, MD, discusses the potential impact of the ongoing, phase 3 TROPION-LUNG01 trial in non–small cell lung cancer.